| Gout
Ilaris vs Naprelan
Side-by-side clinical, coverage, and cost comparison for gout.Deep comparison between: Ilaris vs Naprelan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNaprelan has a higher rate of injection site reactions vs Ilaris based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Naprelan but not Ilaris, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ilaris
Naprelan
At A Glance
SC injection
Every 4-8 weeks
IL-1beta antagonist
Oral
Daily
NSAID
Indications
- Familial Cold Autoinflammatory Syndrome 1
- Muckle-Wells Syndrome
- Cryopyrin-Associated Periodic Syndromes
- TNF receptor-associated periodic fever syndrome (TRAPS)
- Hyperimmunoglobulinemia D
- Familial Mediterranean Fever
- Adult-Onset Still Disease
- Systemic onset juvenile chronic arthritis
- Gout
- Rheumatoid Arthritis
- Degenerative polyarthritis
- Ankylosing spondylitis
- Tendinitis
- Bursitis
- Gout
- Primary dysmenorrhea
Dosing
Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome 1, Muckle-Wells Syndrome For patients >40 kg: 150 mg SC every 8 weeks; for patients >=15 kg and <=40 kg: 2 mg/kg SC every 8 weeks (inadequate response in pediatric patients: 3 mg/kg every 8 weeks).
TNF receptor-associated periodic fever syndrome (TRAPS), Hyperimmunoglobulinemia D, Familial Mediterranean Fever For patients >40 kg: 150 mg SC every 4 weeks (may increase to 300 mg every 4 weeks if response is inadequate); for patients <=40 kg: 2 mg/kg SC every 4 weeks (may increase to 4 mg/kg every 4 weeks if response is inadequate).
Adult-Onset Still Disease, Systemic onset juvenile chronic arthritis For patients >=7.5 kg: 4 mg/kg (maximum 300 mg) SC every 4 weeks.
Gout 150 mg SC as a single dose; if re-treatment is required, an interval of at least 12 weeks must elapse before a new dose.
Rheumatoid Arthritis, Degenerative polyarthritis, Ankylosing spondylitis 750 mg or 1,000 mg once daily; may be increased to 1,500 mg once daily for limited periods when a higher level of anti-inflammatory/analgesic activity is required.
Tendinitis, Bursitis, Primary dysmenorrhea 1,000 mg once daily; for patients requiring greater analgesic benefit, 1,500 mg may be used for a limited period; total daily dose should not exceed 1,000 mg thereafter.
Gout 1,000-1,500 mg once daily on the first day, followed by 1,000 mg once daily until the attack subsides.
Contraindications
- Confirmed hypersensitivity to canakinumab or to any of the excipients
- Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
- Coronary artery bypass graft (CABG) surgery
Adverse Reactions
Most common (>=10%) nasopharyngitis, injection-site reactions, infections, diarrhea, influenza, rhinitis, nausea, headache, abdominal pain, musculoskeletal pain, vertigo, weight increased
Serious serious infections (pneumonia, varicella, sepsis, intra-abdominal abscess, conjunctivitis, pharyngotonsillitis), macrophage activation syndrome, neutropenia
Postmarketing Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Most common (>=10%) headache, dyspepsia, flu syndrome
Serious cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, hematologic toxicity
Pharmacology
IL-1beta antagonist; canakinumab is a human monoclonal IgG1/kappa antibody that selectively binds human IL-1beta and neutralizes its activity by blocking its interaction with IL-1 receptors, without binding IL-1alpha or IL-1 receptor antagonist, thereby reducing IL-1beta-driven inflammation in autoinflammatory and crystal-induced diseases.
Naproxen is an NSAID with analgesic, anti-inflammatory, and antipyretic properties that acts by inhibiting cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis in peripheral tissues.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ilaris
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Naprelan
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Ilaris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Naprelan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Ilaris
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (1/3)
Naprelan
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$30/momo
Ilaris Co-pay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Naprelan.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IlarisView full Ilaris profile
NaprelanView full Naprelan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.